(Total Views: 556)
Posted On: 02/15/2025 6:11:32 PM
Post# of 154807
FDA & our breast cancer:
"The FDA Fast Track designation is a program that speeds up the development and review of new drugs and biologics, but it doesn't expire."
May 7th, 2019 & Dr. Pestell:
FDA Grants Fast Track Designation to Leronlimab for Metastatic TNBC
Nov. 25th, 2024:
“As we continue to prioritize the development of leronlimab in oncology, Dr. Pestell’s expertise will help CytoDyn maximize opportunities to pursue breakthrough treatment in a variety of cancer indications.”
"The FDA Fast Track designation is a program that speeds up the development and review of new drugs and biologics, but it doesn't expire."
May 7th, 2019 & Dr. Pestell:
FDA Grants Fast Track Designation to Leronlimab for Metastatic TNBC
Nov. 25th, 2024:
“As we continue to prioritize the development of leronlimab in oncology, Dr. Pestell’s expertise will help CytoDyn maximize opportunities to pursue breakthrough treatment in a variety of cancer indications.”
(0)
(0)
